 ESSA Pharma Inc. Nasdaq: EPIX; TSX-V: EPI, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSAs clinical candidate, EPI-7386, at the 2020 Virtual American Urological Association AUA Annual Meeting. 